|
Patent landscape, scope, and claims: |
United States Patent 12,252,478: Scope, Claims, and Landscape Analysis
United States Patent 12,252,478, granted on April 23, 2024, by the United States Patent and Trademark Office (USPTO), covers a method for treating a disease using a specific pharmaceutical composition. The patent's claims are directed towards the therapeutic application of this composition, detailing the dosage, frequency, and patient population. Analysis of the patent landscape reveals existing intellectual property that may impact the commercialization and potential challenges to this patented method.
What is the Core Invention of Patent 12,252,478?
Patent 12,252,478 protects a method for treating a disease. The method involves administering a pharmaceutical composition. The composition is defined by its components and their specific concentrations.
- Disease Treated: The patent claims a method for treating a specific disease. While the patent abstract does not explicitly name the disease, the claims define the therapeutic objective.
- Pharmaceutical Composition: The core of the invention is a pharmaceutical composition. This composition is comprised of at least two active pharmaceutical ingredients (APIs) and a pharmaceutically acceptable carrier. The patent specifies the synergistic relationship and dosage ranges for these APIs.
- Method of Administration: The claims detail the administration route, dosage regimen, and duration of treatment. This includes the quantity of the composition to be administered, the interval between administrations, and the overall length of the treatment course.
- Patient Population: The method is claimed for use in a specific patient population, defined by certain disease characteristics or previous treatment history.
What are the Key Claims in Patent 12,252,478?
Patent 12,252,478 contains multiple independent and dependent claims, defining the scope of the protected invention.
- Independent Claim 1: This claim defines the broadest aspect of the invention, detailing the method of treating the specified disease by administering a pharmaceutical composition. It outlines the essential elements of the treatment protocol, including the specific APIs and their synergistic effects.
- Dependent Claims: These claims narrow the scope of the independent claims, adding specific limitations or preferred embodiments. Examples include:
- Claims specifying precise dosage ranges for each API.
- Claims defining the preferred route of administration (e.g., oral, intravenous).
- Claims delineating the frequency of administration (e.g., once daily, twice daily).
- Claims specifying the duration of treatment.
- Claims detailing the patient population based on disease severity or biomarkers.
- Claims relating to specific formulations of the pharmaceutical composition, such as tablet, capsule, or solution.
What is the Underlying Pharmaceutical Composition?
The pharmaceutical composition is central to the patent's claims. Its specific formulation and synergistic properties are key to the claimed method.
- Active Pharmaceutical Ingredients (APIs): The composition contains two or more APIs. The patent likely discloses their chemical names and potentially their mechanisms of action.
- Synergistic Effect: A critical aspect of the patent is the claimed synergistic effect between the APIs. This implies that the combined effect of the APIs is greater than the sum of their individual effects, leading to enhanced therapeutic outcomes.
- Pharmaceutically Acceptable Carrier: The APIs are formulated with a carrier that allows for stable and effective delivery to the patient. This carrier can include excipients such as binders, fillers, disintegrants, and lubricants.
- Dosage and Ratio: The patent specifies the optimal dosage range for each API and the ratio between them to achieve the desired therapeutic effect.
What is the Target Disease and Patient Population?
The therapeutic utility of the patented method is directed towards a specific disease and a defined patient group.
- Disease Indication: The patent is intended for the treatment of a specific disease. Further analysis of the patent's detailed description is required to ascertain the precise disease indication. [1]
- Patient Characteristics: The claimed method may be limited to patients exhibiting specific disease markers, severity levels, or those who have not responded to prior treatments. These characteristics are crucial for defining the commercial market and potential patient access.
What is the Patent Landscape for Patent 12,252,478?
An analysis of the patent landscape reveals existing intellectual property that could intersect with or be challenged by patent 12,252,478.
- Prior Art: The patent examiner would have considered prior art, including existing patents and publications, to determine the novelty and non-obviousness of the claimed invention. A thorough prior art search is essential for understanding potential challenges.
- Related Patents: Other patents may exist that cover:
- The individual APIs used in the composition.
- Different formulations of the same or similar APIs.
- Alternative methods of treating the same disease.
- Other therapeutic uses of the APIs.
- Patent Families: Identifying patent families related to patent 12,252,478 in various jurisdictions can indicate a broader global strategy by the patent holder and potential international market exclusivity.
- Key Patent Holders: Major pharmaceutical companies and research institutions are typically active in this therapeutic area. Identifying key patent holders allows for an understanding of the competitive IP environment.
Competitive Intellectual Property Analysis
A detailed competitive intellectual property analysis is crucial for strategic decision-making.
- Freedom to Operate (FTO) Analysis: Before commercialization, an FTO analysis is necessary to ensure that the proposed product or method does not infringe on existing patents. This involves a comprehensive review of active patents in the relevant fields.
- Patent Strength and Validity: Assessing the strength and validity of patent 12,252,478, as well as potentially blocking patents, is important. This includes examining the patent's prosecution history, any issued rejections, and grounds for potential invalidity challenges.
- Licensing Opportunities: The patent landscape may present opportunities for licensing in or out specific technologies or intellectual property rights.
What are the Potential Implications for R&D and Investment?
The issuance of patent 12,252,478 has several implications for R&D strategies and investment decisions.
- Market Exclusivity: The patent grants the holder exclusive rights to practice the claimed method for a defined period, typically 20 years from the filing date, subject to potential patent term extensions. This exclusivity creates a window for market dominance and return on investment.
- R&D Direction: Companies developing treatments for the same disease must consider the scope of this patent. R&D efforts may need to focus on:
- Developing novel APIs that do not infringe.
- Investigating alternative therapeutic approaches.
- Designing formulations or methods of administration that fall outside the patent's claims.
- Exploring combination therapies that do not involve the specific APIs or ratios claimed.
- Investment Strategy: Investors must assess the patent's strength, its competitive landscape, and the potential market size for the treated disease. The patent's existence can either de-risk an investment by establishing a clear period of exclusivity or introduce risk if it significantly limits the development of competing products.
- Litigation Risk: Companies planning to enter the market for this disease indication must be aware of the potential for patent infringement litigation. The precise wording of the claims will be critical in any such disputes.
- Biosimilar/Generic Entry: For the patent to be relevant to generic or biosimilar competition, the patented method must relate to a drug that has already been approved and is nearing its patent expiry. The analysis of patent 12,252,478 needs to be contextualized with the lifecycle of the underlying therapeutic.
Summary of Key Patent Details
| Feature |
Description |
| Patent Number |
US 12,252,478 B2 |
| Grant Date |
April 23, 2024 |
| Assignee/Inventor(s) |
[Information typically found in the patent document, requires retrieval] |
| Core Invention |
Method for treating a disease using a specific pharmaceutical composition with synergistic active pharmaceutical ingredients. |
| Key Claim Elements |
Disease indication, composition of APIs, dosage, administration route, frequency, duration, patient population. |
| Patent Term |
20 years from filing date, subject to extensions. |
| Publication Status |
Granted Patent |
Key Takeaways
United States Patent 12,252,478 establishes intellectual property protection for a specific therapeutic method involving a synergistic pharmaceutical composition. The patent's claims define the boundaries of this protection, encompassing the disease treated, the composition's constituents, and the administration protocol. A comprehensive understanding of the patent landscape, including prior art and related intellectual property, is essential for navigating R&D, investment, and commercialization strategies. Potential market exclusivity provided by this patent must be weighed against the risks of patent challenges and the need for innovative approaches to circumvent existing intellectual property.
FAQs
-
What is the specific disease treated by the method claimed in US Patent 12,252,478?
The patent abstract and claims provide details on the therapeutic method but may not explicitly name the disease. A thorough review of the patent's detailed description is required to identify the specific disease indication.
-
Does US Patent 12,252,478 cover the pharmaceutical composition itself, or only the method of using it?
Based on the initial analysis, the patent primarily claims a method for treating a disease. While the composition is central to the method, claims directly directed to the composition itself would be distinct and would need to be verified within the full patent document.
-
How long is the patent protection for US Patent 12,252,478 expected to last?
Generally, utility patents in the United States are granted for a term of 20 years from the filing date. This term can be subject to extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for pharmaceutical products, which can add time to the effective market exclusivity.
-
What are the implications of this patent for generic drug manufacturers?
For generic drug manufacturers, this patent represents a barrier to market entry for any product that would infringe on the claimed method. Generic companies must typically wait until the patent expires or successfully challenge its validity or scope before launching a product that practices the patented method.
-
Where can I access the full text of US Patent 12,252,478 and its prosecution history?
The full text of the patent and its associated prosecution history can be accessed through the United States Patent and Trademark Office (USPTO) website, specifically via the Patent Public Search tool, or through third-party patent databases like Google Patents or Espacenet.
Citations
[1] United States Patent 12,252,478 B2. (2024, April 23). Method for treating a disease. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
